Left Ventricular Ejection Fraction Association with Acute Ischemic Stroke Outcomes in Patients Undergoing Thrombolysis

(1) Background: Little is known about how left ventricular systolic dysfunction (LVSD) affects functional and clinical outcomes in acute ischemic stroke (AIS) patients undergoing thrombolysis; (2) Methods: A retrospective observational study conducted between 2006 and 2018 included 937 consecutive AIS patients undergoing thrombolysis. LVSD was defined as left ventricular ejection fraction (LVEF) < 50%. Univariate and multivariate binary logistic regression analysis was performed for demographic characteristics. Ordinal shift regression was used for functional modified Rankin Scale (mRS) outcome at 3 months. Survival analysis of mortality, heart failure (HF) admission, myocardial infarction (MI) and stroke/transient ischemic attack (TIA) was evaluated with a Cox-proportional hazards model; (3) Results: LVSD patients in comparison with LVEF ≥ 50% patients accounted for 190 and 747 patients, respectively. LVSD patients had more comorbidities including diabetes mellitus (100 (52.6%) vs. 280 (37.5%), p < 0.001), atrial fibrillation (69 (36.3%) vs. 212 (28.4%), p = 0.033), ischemic heart disease (130 (68.4%) vs. 145 (19.4%), p < 0.001) and HF (150 (78.9%) vs. 46 (6.2%), p < 0.001). LVSD was associated with worse functional mRS outcomes at 3 months (adjusted OR 1.41, 95% CI 1.03–1.92, p = 0.030). Survival analysis identified LVSD to significantly predict all-cause mortality (adjusted HR [aHR] 3.38, 95% CI 1.74–6.54, p < 0.001), subsequent HF admission (aHR 4.23, 95% CI 2.17–8.26, p < 0.001) and MI (aHR 2.49, 95% CI 1.44–4.32, p = 0.001). LVSD did not predict recurrent stroke/TIA (aHR 1.15, 95% CI 0.77–1.72, p = 0.496); (4) Conclusions: LVSD in AIS patients undergoing thrombolysis was associated with increased all-cause mortality, subsequent HF admission, subsequent MI and poorer functional outcomes, highlighting a need to optimize LVEF.

[1]  L. Szapáry,et al.  Combination of antiplatelet and anticoagulant therapy, component network meta-analysis of randomized controlled trials , 2022, Frontiers in Cardiovascular Medicine.

[2]  Ya Peng,et al.  Advances in brain-heart syndrome: Attention to cardiac complications after ischemic stroke , 2022, Frontiers in Molecular Neuroscience.

[3]  M. Endres,et al.  Stroke–Heart Syndrome: Recent Advances and Challenges , 2022, Journal of the American Heart Association.

[4]  L. Szapáry,et al.  Antithrombotic therapy for secondary prevention in patients with stroke or transient ischemic attack: A multiple treatment network meta-analysis of randomized controlled trials , 2022, PloS one.

[5]  M. Link,et al.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Journal of the American College of Cardiology.

[6]  P. S. Gill,et al.  Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2021, The Lancet Neurology.

[7]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[8]  J. Bauersachs,et al.  Anticoagulants for stroke prevention in heart failure with reduced ejection fraction , 2021, Clinical Research in Cardiology.

[9]  A. Komócsi,et al.  Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events , 2021, Stroke.

[10]  Ana Catarina Fonseca,et al.  European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke , 2021, European stroke journal.

[11]  G. Barnes Combining antiplatelet and anticoagulant therapy in cardiovascular disease. , 2020, Hematology. American Society of Hematology. Education Program.

[12]  Deepak L. Bhatt,et al.  2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution S , 2020, Journal of the American College of Cardiology.

[13]  H. Wong,et al.  Left ventricular systolic dysfunction is associated with poor functional outcomes after endovascular thrombectomy , 2020, Journal of NeuroInterventional Surgery.

[14]  A. Komócsi,et al.  The role of Direct Oral Anticoagulant in patients with Acute Coronary Syndrome on single or dual antiplatelet regime: review of opportunities and challenges. , 2020, Current clinical pharmacology.

[15]  Hyun-Jai Cho,et al.  Blood pressure and heart failure , 2020, Clinical Hypertension.

[16]  W. Powers,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. , 2019, Stroke.

[17]  Gyeong-Moon Kim,et al.  Long-Term Outcomes of Real-World Korean Patients with Atrial-Fibrillation-Related Stroke and Severely Decreased Ejection Fraction , 2019, Journal of clinical neurology.

[18]  S. Schwab,et al.  Heart Failure in Ischemic Stroke: Relevance for Acute Care and Outcome. , 2019, Stroke.

[19]  D. McManus,et al.  Left Ventricular Ejection Fraction and Clinically Defined Heart Failure to Predict 90-Day Functional Outcome After Ischemic Stroke. , 2019, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[20]  M. Endres,et al.  Stroke–heart syndrome: clinical presentation and underlying mechanisms , 2018, The Lancet Neurology.

[21]  Vincent Thijs,et al.  Prevalence of diabetes and its effects on stroke outcomes: A meta‐analysis and literature review , 2018, Journal of diabetes investigation.

[22]  J. Cleland,et al.  Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease , 2018, The New England journal of medicine.

[23]  W. Powers,et al.  2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2018, Stroke.

[24]  Jieli Chen,et al.  Brain–Heart Interaction: Cardiac Complications After Stroke , 2017, Circulation research.

[25]  B. Kissela,et al.  Prevalence of Positive Troponin and Echocardiogram Findings and Association With Mortality in Acute Ischemic Stroke , 2017, Stroke.

[26]  Jeong-Yoon Choi,et al.  Left ventricular wall motion abnormalities are associated with stroke recurrence , 2017, Neurology.

[27]  S. Sutarni,et al.  Hyperglycemia as a prognosis predictor of length of stay and functional outcomes in patients with acute ischemic stroke , 2017, The International journal of neuroscience.

[28]  W. Nyka,et al.  Left ventricular ejection fraction and aortic stiffness are independent predictors of neurological outcome in acute ischemic stroke , 2016, Journal of hypertension.

[29]  P. Gurbel,et al.  Coagulation Abnormalities in Heart Failure: Pathophysiology and Therapeutic Implications , 2016, Current Heart Failure Reports.

[30]  J. Cha,et al.  Association between Left Ventricular Dysfunction and Functional Outcomes at Three Months in Acute Ischemic Stroke. , 2016, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[31]  H. Kamel,et al.  Left Atrial Enlargement and Stroke Recurrence: The Northern Manhattan Stroke Study , 2015, Stroke.

[32]  A. Arboix,et al.  Cardiovascular risk factors for acute stroke: Risk profiles in the different subtypes of ischemic stroke. , 2015, World journal of clinical cases.

[33]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.

[34]  J. McMurray,et al.  Associations of chronic heart failure with outcome in acute ischaemic stroke patients who received systemic thrombolysis: analysis from VISTA , 2015, European journal of neurology.

[35]  Z. Akpınar,et al.  Neutrophil lymphocyte ratio as a predictor of stroke. , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[36]  H. Milionis,et al.  Characteristics and early and long-term outcome in patients with acute ischemic stroke and low ejection fraction. , 2013, International journal of cardiology.

[37]  H. Krum,et al.  Updated meta‐analysis on antithrombotic therapy in patients with heart failure and sinus rhythm , 2013, European journal of heart failure.

[38]  D. Yavagal,et al.  Revascularization grading in endovascular acute ischemic stroke therapy , 2012, Neurology.

[39]  D. Fatovich,et al.  Thrombolysis in acute ischaemic stroke , 2012, The Lancet.

[40]  D. Inzitari,et al.  The coexistence of heart failure predicts short term mortality, but not disability, in patients with acute ischemic stroke treated with thrombolysis: the Florence area Registry. , 2012, European journal of internal medicine.

[41]  Shunichi Homma,et al.  Warfarin and aspirin in patients with heart failure and sinus rhythm. , 2012, The New England journal of medicine.

[42]  L. Wechsler Intravenous thrombolytic therapy for acute ischemic stroke. , 2011, The New England journal of medicine.

[43]  P. Barber,et al.  EPITHET: Positive Result After Reanalysis Using Baseline Diffusion-Weighted Imaging/Perfusion-Weighted Imaging Co-Registration , 2011, Stroke.

[44]  J. Roquer,et al.  Heart Failure in Acute Ischemic Stroke , 2010, Current cardiology reviews.

[45]  Gregory W Albers,et al.  Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.

[46]  R. Raman,et al.  National Institutes of Health Stroke Scale Certification Is Reliable Across Multiple Venues , 2009, Stroke.

[47]  M. Walsh,et al.  Etiology and pathophysiology of new-onset heart failure: Evaluation by myocardial perfusion imaging , 2009, Journal of Nuclear Cardiology.

[48]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[49]  T. Robinson,et al.  Early neurological deterioration in acute ischaemic stroke: predictors, mechanisms and management , 2008, Postgraduate Medical Journal.

[50]  L. Molina,et al.  Heart failure in acute ischemic stroke , 2008, Journal of Neurology.

[51]  H. Diener,et al.  Predictors of Early Cardiac Morbidity and Mortality After Ischemic Stroke , 2007, Stroke.

[52]  Jamie L Banks,et al.  Outcomes Validity and Reliability of the Modified Rankin Scale: Implications for Stroke Clinical Trials: A Literature Review and Synthesis , 2007, Stroke.

[53]  R. Sacco,et al.  Left Ventricular Systolic Dysfunction and the Risk of Ischemic Stroke in a Multiethnic Population , 2006, Stroke.

[54]  Jae Seung Kim,et al.  Factors associated with decreased cerebral blood flow in congestive heart failure secondary to idiopathic dilated cardiomyopathy. , 2006, The American journal of cardiology.

[55]  S. Sacco,et al.  Contribution of Atrial Fibrillation to Incidence and Outcome of Ischemic Stroke: Results From a Population-Based Study , 2005, Stroke.

[56]  G. Davis,et al.  Cardiorespiratory fitness and walking ability in subacute stroke patients. , 2003, Archives of physical medicine and rehabilitation.

[57]  G. Albers,et al.  ATLANTIS Trial: Results for Patients Treated Within 3 Hours of Stroke Onset , 2002, Stroke.

[58]  K. Werdan,et al.  Cerebrovascular reactivity is impaired in patients with cardiac failure. , 2000, European heart journal.

[59]  V. Salomaa,et al.  Atrial fibrillation and stroke. Mortality and causes of death after the first acute ischemic stroke. , 1997, Stroke.

[60]  G. Lamas,et al.  Ventricular dysfunction and the risk of stroke after myocardial infarction. , 1997, The New England journal of medicine.

[61]  P D Lyden,et al.  Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. , 1996, Circulation.

[62]  David Lee Gordon,et al.  Classification of Subtype of Acute Ischemic Stroke: Definitions for Use in a Multicenter Clinical Trial , 1993, Stroke.

[63]  R. Rosati,et al.  Ischemic cardiomyopathy: the myopathy of coronary artery disease. Natural history and results of medical versus surgical treatment. , 1974, The American journal of cardiology.

[64]  J. Rankin Cerebral Vascular Accidents in Patients over the Age of 60: II. Prognosis , 1957, Scottish medical journal.

[65]  S. Kenchaiah,et al.  Cardiac remodeling in systemic hypertension. , 2004, The Medical clinics of North America.